Prognostic role of sentinel node biopsy in patients with thick melanoma: a meta‐analysis

Rondelli, Fabio; Vedovati, Maria Cristina; Becattini, Cecilia; Tomassini, Gian Marco; Messina, S.; Noya, Giuseppe; Simonetti, S.; Covarelli, Piero

doi:10.1111/j.1468-3083.2011.04109.x

Cited by 31 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 In contrast, multiple studies have demonstrated that the status of the sentinel lymph node is predictive of survival with node-negative patients having a 5-year survival of 56-71% versus 26-48% with node-positive disease. [30][31][32][33][34] In a recent metaanalysis by Rondelli et al, 35 and colleagues SNB status was predictive of survival with a 71% 5-year survival if node(s) was negative for disease and 39% if positive. 35 Our findings are similar with a 5-year DSS of 75.4% for negative sentinel node patients versus 44.1 % in node-positive patients (Fig). In addition, as new immunotherapy regimens for melanoma are studied in the adjuvant setting, the status of SNB may provide important information for patient selection.…”

Section: Discussionmentioning

confidence: 95%

Sentinel lymph node biopsy is prognostic but not therapeutic for thick melanoma

Kachare

Singla

Vohra

et al. 2015

Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Sentinel lymph node biopsy is prognostic but not therapeutic for thick melanoma

Kachare

Singla

Vohra

et al. 2015

Surgery

View full text Add to dashboard Cite

“…Age-related disparities in surgical management of primitive melanoma A significant proportion of patients with thick melanomas do not undergo lymph node staging with SLNB, despite the fact that it has been recommended by guidelines since 1998 and supported by retrospective and prospective institutional data [55][56][57][58][59][60][61][62][63][64][65] There are several possible explanations for this discrepancy. For example, multimorbidity could have precluded the use of SLNB in older patients.…”

mentioning

confidence: 99%

Malignant melanoma in elderly patients: biological, surgical and medical issues

Russo

Ferraú

Antonelli

et al. 2014

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Malignant melanoma is an aggressive tumor with a poor prognosis for patients with advanced disease. Over the last decades, its incidence and mortality has increased in elderly population, impacting significantly on healthcare costs, considering the increase in average age of the world population. Older age is recognized as an independent poor prognostic factor for melanoma, but the scientific community now is wondering if elderly melanoma patients have worse outcome because they are not receiving the same treatment as their younger counterparts. This article summarizes current data on elderly melanoma prevention and early detection and its subsequent management, underling the differences observed between older and younger patients. It also describes age-associated alterations in immunity and how these may impact on anti-melanoma response.

show abstract

“…8,16 DFS was longer in patients with negative SNB, when compared with patients with positive SNB but there was no significant difference in terms of OS in the two groups. The impossibility to obtain significant differences in terms of OS can be explained by the morphology of the survival curves ("banana shaped" curves).…”

Section: Discussionmentioning

confidence: 85%

Biópsia do Gânglio Sentinela em Melanomas Espessos: Estudo Clínico Retrospectivo num Único Centro

Lemos

Vieira

Brinca

et al. 2016

SPDV

View full text Add to dashboard Cite

RESUMO -Introdução:A biopsia do gânglio sentinela é um procedimento genericamente aceite no estdiamento do melanoma. O valor prognóstico desta técnica parece ser mais relevante nos melanomas de espessura intermédia (1-4mm) do que nos melanomas espessos (>4mm). Objectivo: Avaliar o valor prognóstico do estado do gânglio sentinela em doentes com melanoma espesso. Doentes e Métodos: A sobrevivência livre de doença e a sobrevivência global foram estimadas pelo método de Kaplan-Meier e por um modelo de regressão de Cox numa amostra de doentes com melanoma espesso. Resultados: Foram incluídos 43 doentes (52.2% do sexo masculino) com uma média etária de 63,9 anos. A biopsia do gânglio sentinela foi positiva em 20 casos (46,5%). O tempo médio de seguimento foi de 40 meses. Os doentes em que não foram encontradas metástases no gânglio sentinela tiveram uma sobrevivência livre de doença aos 5 anos significativamente maior do que o grupo de doentes com gânglio sentinela positivo (63% versus 19%, p<0.05). A sobrevivência global aos 5 anos foi tendencialmente mais baixa em doentes com gânglio sentinela positivo (52% versus 79%), embora sem significado estatístico. Conclusão: O estado do gânglio sentinela não teve influência estatística na sobrevivência global dos doentes da nossa série de melanomas espessos, provavelmente devido ao risco elevado de metastização por via hemática. Porém, a biopsia do gânglio sentinela forneceu informação prognóstica relevante, uma vez que teve clara influência na sobrevivência livre de doença. PALAVRAS-CHAVE -Biópsia do Gânglio Sentinela; Melanoma; Neoplasias da Pele; Prognóstico; Taxa de Sobrevida. Sentinel Lymph Node Biopsy in Thick Melanoma

show abstract

Prognostic role of sentinel node biopsy in patients with thick melanoma: a meta‐analysis

Abstract: The results of this analysis showed that thick melanoma patients with a positive SLN had a significantly worse survival compared with SLN negative patients, thus supporting the routine adoption of SLN biopsy as a prognostic tool also for this subgroup of patients.

Cited by 31 publications

References 38 publications

Sentinel lymph node biopsy is prognostic but not therapeutic for thick melanoma

Sentinel lymph node biopsy is prognostic but not therapeutic for thick melanoma

Malignant melanoma in elderly patients: biological, surgical and medical issues

Biópsia do Gânglio Sentinela em Melanomas Espessos: Estudo Clínico Retrospectivo num Único Centro

Contact Info

Product

Resources

About